A. Lamrani-Ghaouti

发表

First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

R. Houot, F. Jardin, K. Hoang-Xuan, 2020 .

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.

S. Chevret, J. Grob, T. Jouary, 2022, European journal of cancer.

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

P. Marino, G. Gravis, J. Ciccolini, 2023, BMC Cancer.

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

S. Chevret, B. Escudier, S. Oudard, 2020 .

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas

S. Chevret, T. Jouary, L. Gambotti, 2023, Cancer immunology, immunotherapy : CII.

121MO Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial

D. Pasquier, A. Tallet, S. Racadot, 2021, Annals of Oncology.

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

J. Blay, F. Bertucci, S. Chevret, 2021 .

Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort

J. Salleron, D. Peiffert, J. Faivre, 2022, BMC cancer.

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

J. Blay, F. Bertucci, S. Chevret, 2020 .

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

J. Blay, F. Bertucci, S. Chevret, 2023, The Lancet. Oncology.